

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/320556119>

# Reference values for oxygen saturation from sea level to the highest human habitation in the Andes in acclimatised persons

Article in *Thorax* · October 2017

DOI: 10.1136/thoraxjnl-2017-210598

CITATIONS

0

READS

10

17 authors, including:



**David Callacondo**

Universidad Peruana Cayetano Heredia

23 PUBLICATIONS 139 CITATIONS

SEE PROFILE



**Margarita Posso**

Hospital de la Santa Creu i Sant Pau

34 PUBLICATIONS 117 CITATIONS

SEE PROFILE



**Erick Bravo**

National University of San Marcos

13 PUBLICATIONS 1 CITATION

SEE PROFILE



**Angel Quispe-Mauricio**

Hospital Universitario Principe de Asturias

22 PUBLICATIONS 54 CITATIONS

SEE PROFILE

## Reference values for oxygen saturation from sea level to the highest human habitation in the Andes in acclimatised persons

### ABSTRACT

Oxygen saturation, measured by pulse oximetry (SpO<sub>2</sub>), is a vital clinical measure. Our descriptive, cross-sectional study describes SpO<sub>2</sub> measurements from 6289 healthy subjects from age 1 to 80 years at 15 locations from sea level up to the highest permanent human habitation. Oxygen saturation measurements are illustrated as percentiles. As altitude increased, SpO<sub>2</sub> decreased, especially at altitudes above 2500 m. The increase in altitude had a significant impact on SpO<sub>2</sub> measurements for all age groups. Our data provide a reference range for expected SpO<sub>2</sub> measurements in people from 1 to 80 years from sea level to the highest city in the world.

### BACKGROUND

Pulse oximetry has led to a great advancement in patient management offering non-invasive estimation of arterial oxygen saturation. It is routinely used in emergency departments, wards, intensive care and other medical situations. At high altitudes, physiological ventilation parameters like plasma

bicarbonate are different.<sup>1</sup> Pulse oximetry measurements of oxygen saturation (SpO<sub>2</sub>) are lower at altitude compared with those at sea level. However, the expected SpO<sub>2</sub> at a given altitude is unclear and has been suggested as a range of values rather than a specific number.<sup>2</sup>

### METHODS

#### Subjects

Data were collected from 15 locations at different altitudes from sea level to the highest permanent human habitation located in a remote area at 5100 m in Puno, Peru, a city named La Rinconada.<sup>3</sup>

We recruited subjects between 1 and 80 years with a minimum of 2 months residence at the place of evaluation because alveolar gas composition is different after acclimatisation.<sup>4</sup> Exclusion criteria were based on history and clinical examination. Subjects with a history of the following were excluded: habitual smoker ( $\geq 1$  cigarette day), ongoing pregnancy, chronic cardiorespiratory disease, anaemia, polycythaemia or having received a blood transfusion in the last 6 months and with abnormal findings in physical examination. Children who were asleep at the time of measurement of SpO<sub>2</sub> and subjects with painted nails or deformities in measurement locations were also excluded. Informed consent was obtained from all subjects or their guardians.

### Measurement of SpO<sub>2</sub>

SpO<sub>2</sub> was measured using a pulse oximeter (Nellcor 560, Hayward, California, USA), with sensors appropriate to the weight of the subject. SpO<sub>2</sub> measurements were recorded every 10 s for a total of six measurements and the average was used to determine SpO<sub>2</sub> for each study subject, as described in previous studies.<sup>5</sup>

At the end of the study, we compared SpO<sub>2</sub> measurements against simultaneous measurements of arterial oxygen saturation (SaO<sub>2</sub>) by arterial blood gases in 10 hospitalised patients, at sea level. The average of (SaO<sub>2</sub> - SpO<sub>2</sub>) was 1.48%. This was within the expected value of  $\pm 2\%$  for a range of SpO<sub>2</sub> measurements between 70% and 100% reported by the manufacturer.<sup>6</sup>

To assess the reproducibility of our data, at 5100 m, we measured SpO<sub>2</sub> twice in 23 subjects waiting 30 min before taking the second measurement. For this test, we used the Fingertip Pulse Oximeter MD300C1. The average difference between SpO<sub>2</sub> measured by the two devices (Nellcor-MD300C1) was  $-0.8\%$ .

### STATISTICAL ANALYSIS


Descriptive statistics were used to summarise characteristics of the subjects.

### Constructing oxygen centile charts


SpO<sub>2</sub> data were entered into Microsoft Excel and were analysed and charted using Stata (Intercooled 10, Stata Corp, College Station, Texas, USA). The SpO<sub>2</sub> centiles were calculated using the LMS method of Cole and Green<sup>7,8</sup> and fitted using the LMSChartMaker Light V.2.3 (Institute of Child Health, London, England). These values were then used to illustrate the 2.5th, 10th, 25th, 50th, 75th, 90th and 97.5th centile for SpO<sub>2</sub> for each age group according to residential altitude (see online supplement).

### RESULTS

We studied subjects residing at 15 specific altitudes. We initially evaluated 6601 subjects. Three hundred and twelve met exclusion criteria. A total of 6289 subjects were studied: 47.2% (n=2967) males and 52.8% females (n=3322). The median (IQR) for all SpO<sub>2</sub> measurements at each altitude (metre) were respectively: 99 (98–99) at 154 m; 99 (98–99) at 562 m; 98 (97–99) at 1400 m; 97 (96–98) at 2000 m; 97 (96–99) at 2335 m; 96 (95–97) at 2500 m; 95 (94–96) at 2880 m; (92–95) at 3250 m; 92 (90–93) at 3600 m; 90 (88–91) at 3950 m; 87 (85–89) at 4100 m; 87 (85–89) at 4338 m; 87 (85–89) at 4500 m;



**Figure 1** 2.5th, 10th, 25th, 50th, 75th, 90th, and 97.5th SpO<sub>2</sub> percentiles for all subjects according to altitude. (n=6289) distributed by the following altitudes: 154 m (n=709), 562 m (n=405), 1400 m (n=315), 2000 m (n=209), 2335 m (n=522), 2500 m (n=416), 2880 m (n=404), 3250 m (n=422), 3600 m (n=361), 3950 m (n=350), 4100 m (n=644), 4338 m (n=457), 4500 m (n=525), 4715 m (n=251), 5100 m (n=299).



**Figure 2** 2.5th, 10th, 25th, 50th, 75th, 90th, and 97.5th SpO<sub>2</sub> percentiles for children. (A) Represents children 1–5 years (n=994) with N for specific altitude in the same order as [figure 1](#) (n=64, 91, 69, 26, 70, 87, 95, 140, 30, 46, 91, 47, 36, 28, 74). (B) Represents children 6–17 years (n=2379) (n=281, 144, 146, 116, 171, 234, 122, 181, 117, 202, 117, 126, 121, 133, 168). Adults 18–50 (C) (n=2195) (n=310, 120, 28, 40, 239, 70, 134, 56, 136, 45, 297, 247, 353, 68, 52) and 51–80 years (D) (n=721) (n=54, 50, 72, 27, 42, 25, 53, 45, 78, 57, 139, 37, 15, 22, 5), adults according to altitude.

85 (83–88) at 4715 m; 81 (78–84) at 5100 m.

### Oxygen saturation measurements

SpO<sub>2</sub> measurements illustrated as percentiles are shown for all subjects in [figure 1](#), and by age group (1–5, 6–17, 18–50 and 51–80 years) in [figure 2](#). The figures show that for all age groups, as altitude increased, SpO<sub>2</sub> decreased, especially at altitudes above 2500 m (see online supplement tables).

### DISCUSSION

We obtained measurements from over 6000 subjects, from 1 to 80 years old, from sea level to the highest permanent human habitation located in Peru at 5100 m.<sup>3</sup> This is the first study to provide reference charts for the expected range of SpO<sub>2</sub> measurements by age group and altitude using centiles by the LMS method.

We have shown the expected reduction of SpO<sub>2</sub> with altitude, an effect that is more evident at altitudes over 2500 m. We have also shown increased variability in the range of SpO<sub>2</sub> measurements at higher altitudes. Our observation could be explained by a genetic variability in the hypoxic ventilatory response. It is noteworthy that at 5100 m, the median SpO<sub>2</sub> of 81% could correspond to a PO<sub>2</sub> less

than 50 mm Hg according to the oxygen dissociation curve. This is less than half of the normal PO<sub>2</sub> at sea level.

Pulse oximetry utility in clinical care outside the operating theatre has been supported by studies at sea level and at high altitude.<sup>9</sup> Having a reference value for SpO<sub>2</sub> is needed in clinical management at high altitude locations.

There are some limitations to our findings and analysis. We did not enrol subjects over 80 years or children less than 1 year. Our study does not apply to non-acclimatised individuals. We did take a clinical history and conducted a physical examination of all subjects. However, we did not conduct further testing, such as chest radiography, spirometry or haemoglobin measurement, to rule out pathology not evidenced by clinical examination. Therefore, in evaluating patients at high altitude, their history and clinical presentation must be incorporated into deciding whether an individual SpO<sub>2</sub> measurement should raise concern for a patient at their usual residential altitude.

All our subjects were Andean Natives and Hispanics and care should therefore be taken in applying these results to other ethnicities and to other parts of the world. For example, Tibetans have different physiological traits

for the oxygen delivery process<sup>10</sup> and might have different SpO<sub>2</sub> measurements at the same altitude as our subjects.

In conclusion, our data provide a reference range for SpO<sub>2</sub> in people from 1 to 80 years from sea level to the highest city in the world, contributing to global knowledge of expected SpO<sub>2</sub> measurements at any given habitable altitude.

Jose Rojas-Camayo,<sup>1</sup> Christian Richard Mejia,<sup>2</sup> David Callacondo,<sup>3</sup> Jennifer A Dawson,<sup>4</sup> Margarita Posso,<sup>5</sup> Cesar Alberto Galvan,<sup>6</sup> Nadia Davila-Arango,<sup>7</sup> Erick Anibal Bravo,<sup>8</sup> Viky Yanina Loescher,<sup>9</sup> Magaly Milagros Padilla-Deza,<sup>10</sup> Nora Rojas-Valero,<sup>11</sup> Gary Velasquez-Chavez,<sup>12</sup> Jose Clemente,<sup>13</sup> Guisela Alva-Lozada,<sup>14</sup> Angel Quispe-Mauricio,<sup>15</sup> Silvana Bardalez,<sup>16</sup> Rami Subhi<sup>17</sup>

<sup>1</sup>Instituto de Investigaciones de la Altura, Universidad Peruana Cayetano Heredia, Lima, Peru

<sup>2</sup>Escuela de Medicina Humana, Universidad Continental, Huancayo, Peru

<sup>3</sup>School of Medicine, Faculty of Health Sciences, Universidad Privada de Tacna, Tacna, Peru

<sup>4</sup>The Royal Women's Hospital, Melbourne, Australia

<sup>5</sup>Department of Epidemiology and Evaluation, Hospital del Mar Medical Research Institute, Barcelona, Spain

<sup>6</sup>Centro de Referencia Nacional de Alergia, Asma e Inmunología (CERNAAI), Instituto Nacional de Salud del Niño, Lima, Peru

<sup>7</sup>Hospital Clínico Universitario de Salamanca, Salamanca, Spain

<sup>8</sup>Hospital Nacional Dos de Mayo, Institute of Clinical Research, Lima, Peru  
<sup>9</sup>Mount Sinai Medical Center, Miami, USA  
<sup>10</sup>Resocentro, Lima, Peru  
<sup>11</sup>Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru  
<sup>12</sup>Centro de Salud Zalfonada, Zaragoza, Spain  
<sup>13</sup>Hospital Nacional Hipólito Unanue, Lima, Peru  
<sup>14</sup>Hospital Nacional Edgardo Rebagliati Martins, Lima, Peru  
<sup>15</sup>Hospital Universitario Príncipe de Asturias, Madrid, Spain  
<sup>16</sup>Clinica Concebir, Lima, Peru  
<sup>17</sup>Center for international Child Health, University of Melbourne, Royal Children's Hospital, Melbourne, Australia

**Correspondence to** Dr Jose Rojas-Camayo, Universidad Peruana Cayetano Heredia, Lima 31, Peru; [joserojas18@hotmail.com](mailto:joserojas18@hotmail.com)

**Contributors** All authors were involved in the design of the study and collection of clinical data. JAD, JRC and CRM performed the data analysis. JRC, CRM, DC, JAD, MP, VYL and RS drafted the final manuscript and all authors reviewed and made amendments.

**Competing interests** None declared.

**Patient consent** Obtained.

**Ethics approval** Ethics Committee at Hospital Nacional Docente Madre Niño San Bartolomé, Lima-Peru.

**Provenance and peer review** Not commissioned; externally peer reviewed.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/thoraxjnl-2017-210598>)



CrossMark

**To cite** Rojas-Camayo J, Mejia CR, Callacondo D, *et al.* *Thorax* Published Online First: [please include Day Month Year]. doi:10.1136/thoraxjnl-2017-210598

Received 5 June 2017

Revised 6 September 2017

Accepted 25 September 2017

*Thorax* 2017;**0**:1–3.

doi:10.1136/thoraxjnl-2017-210598

## REFERENCES

- 1 Ramirez-Sandoval JC, Castilla-Peón MF, Gotés-Palazuelos J, *et al.* Bicarbonate values for healthy

residents living in cities above 1500 meters of altitude: a theoretical model and systematic review. *High Alt Med Biol* 2016;17:85–92.

- 2 Luks AM, Swenson ER. Pulse oximetry at high altitude. *High Alt Med Biol* 2011;12:109–19.
- 3 West JB. Highest permanent human habitation. *High Alt Med Biol* 2002;3:401–7.
- 4 Rahn H, Otis AB. Man's respiratory response during and after acclimatization to high altitude. *Am J Physiol* 1949;157:445–62.
- 5 Beall CM, Almasy LA, Blangero J, *et al.* Percent of oxygen saturation of arterial hemoglobin among Bolivian Aymara at 3,900–4,000 m. *Am J Phys Anthropol* 1999;108:41–51.
- 6 Covidien. Operator's Manual. OxiMax N-560. pulse oximeter. [http://www.medtronic.com/content/dam/covidien/library/us/en/product/pulse-oximetry/N560\\_OperatorsManual\\_EN\\_10096204A00.pdf](http://www.medtronic.com/content/dam/covidien/library/us/en/product/pulse-oximetry/N560_OperatorsManual_EN_10096204A00.pdf) (accessed 23 July 2017).
- 7 Cole TJ, Green PJ. Smoothing reference centile curves: the LMS method and penalized likelihood. *Stat Med* 1992;11:1305–19.
- 8 Cole TJ. Fitting smoothed centile curves to reference data. *J R Stat Soc Ser A Stat Soc* 1988;151:385–418.
- 9 Reuland DS, Steinhoff MC, Gilman RH, *et al.* Prevalence and prediction of hypoxemia in children with respiratory infections in the Peruvian Andes. *J Pediatr* 1991;119:900–6.
- 10 Beall CM. Two routes to functional adaptation: Tibetan and Andean high-altitude natives. *Proc Natl Acad Sci U S A* 2007;104 Suppl 1:8655–60.

**THORAX**

## Reference values for oxygen saturation from sea level to the highest human habitation in the Andes in acclimatised persons

Jose Rojas-Camayo, Christian Richard Mejia, David Callacondo, Jennifer A Dawson, Margarita Posso, Cesar Alberto Galvan, Nadia Davila-Arango, Erick Anibal Bravo, Viky Yanina Loescher, Magaly Milagros Padilla-Deza, Nora Rojas-Valero, Gary Velasquez-Chavez, Jose Clemente, Guisela Alva-Lozada, Angel Quispe-Mauricio, Silvana Bardalez and Rami Subhi

*Thorax* published online October 20, 2017

---

Updated information and services can be found at:

<http://thorax.bmj.com/content/early/2017/10/20/thoraxjnl-2017-210598>

---

*These include:*

### References

This article cites 9 articles, 0 of which you can access for free at: <http://thorax.bmj.com/content/early/2017/10/20/thoraxjnl-2017-210598#BIBL>

### Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

### Notes

---

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>